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Abstract
Background: Renal cell carcinoma developing metastases in the bladder is rare. Bladder metastasis due to a
papillary type of renal cell carcinoma is rarer. Such metastases could be synchronous or metachronous.
Case presentation: Here we present a 55-year-old female patient with haematuria who underwent left nephro-
ureterectomy for a suspected urothelial tumour. Histopathology revealed it to be a type 2 papillary renal cell
carcinoma. Eighteen months later, she developed metachronous bladder metastasis of the papillary renal cell
carcinoma which was treated with total cystectomy. Currently, she is on interferon therapy.
Conclusions: These bladder metastases from renal cell carcinoma could be due to drop metastases, lymphatic
spread or haematogenous spread. The exact mechanism in a given case appears to be unpredictable.
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Abbreviations: CT KUB, Computerised tomography of the kidney, ureter and bladder; ECOG, Eastern Cooperative
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Background
Renal cell carcinoma (RCC), the commonest renal ma-
lignancy in adult is known to have distant metastasis in
about 20–30 % of patients at the time of diagnosis [1].
Another 20 % will develop metastasis during the follow-
up [1]. Even early stage RCC confined to the kidney has
the potential to develop metastases after surgery with
curative intent. Common sites of metastases include the
lung (50–60 %), lymph node (40–60 %), liver (30–40 %),
and bone (30–40 %) [2]. Rare sites include the parotid
gland, eye and urinary bladder [3]. About 65 cases have
been published in the literature with bladder metastases
of RCC [4]. Clear cell renal carcinoma is the commonest
(92 %) histological type [4]. Only two cases of papillary
type of renal cell carcinoma have been reported among
those 65 cases. Here we describe a case of papillary type
2 carcinoma of the kidney developing metachronous me-
tastases in the urinary bladder.
Case presentation
A 55-year-old mother of two children developed haema-
turia, and the contrast enhanced computerised tomography
of the urinary tract (CT KUB) showed a solid mass in the
left kidney close to its hilum suggestive of a urothelial car-
cinoma of the renal pelvis. The mass was heterogenous
with contrast enhancement and was 5.6 cm× 4.5 cm in di-
mensions. There was no vascular involvement or lymph-
adenopathy. The right kidney, ureters and bladder were
normal. Cystoscopy did not show any mucosal lesions. She
was a non-smoker and was having well-controlled hyper-
tension. She had open left nephro-ureterctomy through loin
and left lower abdominal incisions. The histology showed a
type 2 papillary renal cell carcinoma—stage pT1b. Fuhrman
grade was 3. She was followed up with no adjuvant therapy.
Eighteen months later, her routine follow-up US scan
of KUB showed a mucosal lesion in the left base of the
bladder which was confirmed by a CT scan (Fig. 1). It
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was confined to the bladder wall. She underwent trans-
urethral resection of the bladder lesion which showed
metastatic deposits of a high-grade papillary renal cell
carcinoma (Figs. 2a and 2b). Immunohistochemistry
showed strong membrane positivity for CD10 (Fig. 2c)
while CK7 and CK20 were negative (Fig. 2d). Despite
transurethral resection, the tumour was growing rapidly
and she underwent total cystectomy and neobladder
formation. Since then, she has interferon alpha injec-
tions thrice a week. Ten months after cystectomy, she
developed a lung metastasis. She continues to have
interferon and is well with an Eastern Cooperative
Oncology Group (ECOG) performance status of 1,
6 months after the diagnosis of the lung metastasis.
Discussion
Metastases to the urinary bladder occur in less than 1 %
of solid tumours [5]. Renal cell carcinoma developing
metastases in the bladder is extremely rare with an inci-
dence of 0.3 % [6]. Clear cell carcinoma is the
Fig. 1 CT scan showing a large irregular mucosal lesion in the left base of the bladder
Fig. 2 H&E staining and immunohistochemistry of the bladder lesion. a Papillary renal cell carcinoma involving the bladder wall (H&E stain, ×100).
b Papillary renal cell carcinoma involving the bladder wall (H&E stain, ×200). c Immunohistochemistry showing strong membrane positivity for
CD10 (×200). d immunohistochemistry showing negativity for CK20 (×200)
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commonest histological variety of renal cell carcinoma
that leads to bladder metastases [4]. Papillary carcinoma is
less commonly involved, followed by collecting duct car-
cinoma and chromophobe cell carcinoma [4]. Hoffman re-
ported the first case of renal cell carcinoma developing
metastases in the bladder in 1907 [5]. Bladder metastases
can be synchronous or metachronous. Metachronous me-
tastases are commoner (77 %) [4]. The median time for
metachronous bladder metastases following the diagnosis
of renal cell carcinoma is 33 months [4]. The overall prog-
nosis is poor in these patients with most patients dead
within 1 year of diagnosing the bladder metastases.
Generally, papillary renal cell carcinoma has a less po-
tential for metastases than clear cell carcinoma and has
a better prognosis [7]. However, when metastases de-
velop, papillary renal cell carcinoma behaves more ag-
gressively than patients with a metastatic clear cell type
of renal cell carcinoma [8]. The exact reason for this un-
usual behaviour is unknown.
The underlying mechanism of metastatic spread is de-
batable with several possible modes described [9]. One is
“drop metastases” due to malignant cells moving along
the urinary tract and getting implanted on the bladder
epithelium [10]. This is supported by reports where the
RCC deposit was free floating without attachment to the
urothelium in histological examination and by the pres-
ence of cancer cells in urine of patients with RCC [11].
In others, bladder lesions are found along with meta-
static deposits in other distant organs as well, suggestive
of a hematogenous spread. However, another subgroup
develops muscle-invasive or deep metastatic lesions in
the bladder especially located near the ureteric orifice
suggestive of spread along the lymphatics as emboli [12].
In these patients, retrograde venous embolisation of
tumour cells is also a possibility [6]. In our patient, as
the dissection of the kidney and ureter were done while
the ureter was left patent and the fact that her primary
lesion was close to the renal pelvis with haematuria as a
symptom, drop metastases would have been more likely
[13]. However, the lesion was deep in the bladder wall
near the ureteric orifice which makes the peri-ureteric
spread or hematogenous spread also possible. The latter
mechanism is more plausible as she had a poorer prog-
nosis with development of lung metastases within
10 months of surgery to remove bladder metastases.
Those with drop metastases have a much better progno-
sis [14]. More than one mechanism of metastatic spread
operating in a single case is also a possibility as a similar
combination of characteristics as in our patient was
noted in a case of clear cell carcinoma leading to bladder
metastases after 12 years of nephrectomy where the le-
sion was deep but was located close to the ureteric ori-
fice [15]. These contradictions regarding the mechanism
of metastatic spread is nothing unusual in RCC as there
are cases of regional recurrence after 31 years [16] and
distant metastases 24 years after nephrectomy [17].
First, metastasectomy for RCC was done by Barney in
1939 in a patient with a solitary metastatic lesion in the
lung who died 23 years later of cardiac disease [18]. The
decision to perform metastasectomy is usually made ac-
cording to various prognostic criteria: the site and num-
ber of metastases, the completeness of resection of the
primary tumour, the performance status and the disease-
free interval from treatment of the primary tumour to
the diagnosis of metastatic disease [19]. Although im-
proved survival after metastasectomy is still debatable,
surgical intervention can provide palliation for symp-
tomatic metastatic disease [20].
Endoscopic resection of the bladder metastatic lesion
will confirm the diagnosis and may be considered ad-
equate as the primary treatment in cases of drop metas-
tases. Others with deeper lesions would require more
extensive surgical treatment including partial or total
cystectomy if the metastases are confined to the bladder.
Since most of these patients are likely to have systemic
metastases, they are given systemic therapy with
interleukin-2 or tyrosine kinase inhibitors. The 3-year
survival rate of patients with a solitary metastasis is
around 80 % [20]. However, about 50 % of patients with
multiple metastases have a life expectancy less than
1 year after diagnosis.
Conclusions
Although rare, papillary renal cell carcinoma can develop
metastases in the bladder. Drop metastases, haematogen-
ous spread, embolisation through lymphatics and retro-
grade venous embolisation are the suggested possible
mechanisms. The exact mechanism in a given case ap-
pears to be unpredictable. It may be possible that several
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